Champions Oncology, Inc. · NASDAQ:CSBR
Champions Oncology — Investor Presentation (January 2020)
26 slides from Champions Oncology's investor presentation, Jan 3, 2020
Slide 1: Investor Relations Presentation – December 2019
INVESTOR RELATIONS PRESENTATION – DECEMBER 2019
Slide 2: Notice of Forward-Looking Statements
NOTICE OF FORWARD-LOOKING STATEMENTS This presentation contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking
Slide 3: Our Mission: Innovative Research Platforms Transforming Cancer Research
OUR MISSION… Providing The Innovative Research Platforms Transforming Cancer Research 3
Slide 4: Champions' Research Platforms
CHAMPIONS’ RESEARCH PLATFORMS8
Slide 5: Industry Challenge: Complex Biology, Complicated Regulatory Landscape, Low Rate of Success
INDUSTRY CHALLENGE: Complex Biology, Complicated Regulatory Landscape, Low Rate of Success. • HIGH FAILURE RATE • 93% of drugs fail in clinical trials • SKYROCKETING R&D COSTS • $1.2 billion average capital outlay per approved drug • PATIENT RESPONSES REMAIN LOW EVEN FOR APPROVED DRUGS • 10% respons
Slide 6: Champions' Foundational Platform: Simulating Patient Responses with PDX Modeling
CHAMPIONS’ FOUNDATIONAL PLATFORM: A Company Built on Innovation - Simulating Patient Responses with PDX Modeling A demonstrated predictive value of 87%-94% for Champions TumorGraft® PDX models* Izumchenko E et al, 2017. Ann Oncol. 5
Slide 7: The Global Leading PDX Bank
THE GLOBAL LEADING PDX BANK Other tumor types 15 10 17 Colorectal 17 Adrenocortical Duodenal Hepatoblastoma Small bowel Sarcoma Ampullary Endometrial Histiocytoma Small intestinal 48 Lung (NSCLC/SCLC) Bladder ETANTR Merkel cell Sialoblastoma 19 170 Pancreatic Cervical Fallopian tube Myxoma Testicula
Slide 8: Champions Global Presence
CHAMPIONS GLOBAL PRESENCE A Global Organization Built Through Offering Innovative Solutions Commercial Overview: • Active in 400+ biopharma globally • Customer base consists of biopharma of all size • 500+ contracts booked in past 12 months • Operations in US & Europe • Sales teams in US, Europe and
Slide 9: Champions Innovative Platforms: Comprehensive Suite of PDX Platforms
CHAMPIONS INNOVATIVE PLATFORMS: Now Offering A Comprehensive Suite of PDX Platforms Solid & Heme PDX Flow cytometry • In vivo Pharmacology o Simulating clinical trials o Drug efficacy studies o Pharmacodynamic analysis Ex Vivo/In Vitro Histology • Ex Vivo Pharmacology o Extensive 2D and 3D platforms
Slide 10: Providing Advanced Immune Oncology Research Solutions
CHAMPIONS INNOVATIVE PLATFORMS: Providing Advanced Immune Oncology Research Solutions Solid & Heme PDX Flow cytometry • Novel humanized mouse systems developed Ex Vivo/In Vitro Histology • Classic & transgenic syngeneic models • Advanced flow cytometry & histology endpoint analysis Humanized Models
Slide 11: Providing Sophisticated Biomarker Analyses
CHAMPIONS INNOVATIVE PLATFORMS: Providing Sophisticated Biomarker Analyses • Advanced flow cytometry platforms Solid & Heme PDX Flow cytometry o 24 color o Superior analytic methodology o Complex study design Ex Vivo/In Vitro Histology • Comprehensive array of histology o IHC and IF o Single and mul
Slide 12: Leverage Experience to Build a Data Platform
CHAMPIONS INNOVATIVE PLATFORMS: Solid & Heme PDX Flow cytometry Data Analytics Ex Vivo/In Vitro Histology Leverage Experience to Build a Data Platform: Humanized Models Plate-Based • Use data for predictive insights into MOA • Use data to guide machine mPDX, Syngeneic learning in biomarker or & huSy
Slide 13: Leverage Experience to Build a Data Platform
CHAMPIONS INNOVATIVE PLATFORMS: Solid & Heme PDX Flow cytometry Data Analytics Ex Vivo/In Vitro Histology Leverage Experience to Build a Data Platform: Humanized Models Plate-Based • Use data for predictive insights into MOA • Use data to guide machine mPDX, Syngeneic learning in biomarker or & huSy
Slide 14: Developing a Data Platform: Leveraging Data to Transform Precision Medicine
DEVELOPING A DATA PLATFORM Leveraging Data to Transform Precision Medicine • Integration with public datasets • Analytic visualizations: Alternative Champions’ The Problem Interactive oncogenic signaling Dataset o Datasets pathways. o Oncoprints. Full Exome and o Differential expression Ideal precis
Slide 15: Providing The Innovative Platforms Transforming Cancer Research
CHAMPIONS INNOVATIVE PLATFORMS: Providing The Innovative Platforms Transforming Cancer Research Solid & Heme PDX Flow cytometry Ex Vivo/In Vitro Histology Humanized Models Plate-Based mPDX, Syngeneic Data Analytics & huSyngeneic Discovery Preclinical Translational Clinical
Slide 16: Oncology Market Overview
ONCOLOGY MARKET OVERVIEW 8
Slide 17: Oncology Market Continues to Soar
ONCOLOGY MARKET CONTINUES TO SOAR Oncology market will double between 2019 and 2024 • The oncology CRO market is expected to reach $44B by 2021 • Clinical flow market is expected to reach $1B by 2021 Global Market Sizes by 2021 Global Pharma $752B 6% CAGR Global Oncology $175B 12% CAGR Global Oncolo
Slide 18: Market Positioning & Brand Image
MARKET POSITIONING & BRAND IMAGE Industry Leader Biggest, brightest & best Innovative Offerings Pioneering & comprehensive Trusted & Quality Flexible & consultative operational delivery Scientific Superiority Strong scientific expertise in oncology at all levels 10
Slide 19: Oncology Services Competitive Landscape
ONCOLOGY SERVICES COMPETITIVE LANDSCAPE Champions Oncology’s existing business segments are positioned as being “High-Valued, Scientific & Innovative Platforms” Expensive Pharmacology Platforms Expensive Biomarker Platforms Inexpensive Inexpensive Off the shelf Innovative Off the shelf Innovative 11
Slide 20: History of Aggressive Growth
HISTORY OF AGGRESSIVE GROWTH Champions Oncology continues to build infrastructure to capitalize on growing industry demand • Continued Platform Innovation • Expanding to a Global Footprint • Increasing Lab Capabilities • Creating Extensive Pharma Relationships 400+ Customers • Including 18 of the to
Slide 21: Financial Overview
FINANCIAL OVERVIEW 8
Slide 22: Revenue Growth and Profitability
REVENUE GROWTH AND PROFITABILITY $35,000,000 • 30%+ annual revenue growth $30,000,000 from FY 2016 – FY 2019 $25,000,000 • Breakeven results in FY 2018 $20,000,000 • FY 2019 increase in expenses is due to investment in $15,000,000 product expansion to continue sustain revenue expansion $10,000,000 •
Slide 23: Financial Results
FINANCIAL RESULTS 3 Months Ended October 31, 12 Months Ended April 30, 2019 2018 2019 2018 Operating Revenue Translational Oncology Solutions $7,394 $6,444 $25,790 $18,786 Personalized Oncology Solutions 232 250 1,277 1,455 Total Operating Revenue $7,626 $6,694 $27,067 $20,241 Costs and Operating Ex
Slide 24: Financial Results & Multi Year Term Vision
FINANCIAL RESULTS & MULTI YEAR TERM VISION ($ in millions) FY 2021 Estimate FY 2022 Estimate FY 2023 Estimate FY 2024 Estimate Revenue $42.25 $54.93 $70.03 $87.54 Cost of Sales $20.48 $25.90 $32.76 $40.63 GP% 52% 53% 53% 54% R&D $5.68 $6.11 $6.57 $7.06 as a % of revenue 13% 11% 9% 8% Sales and Marke
Slide 25: Strategies for Continued Growth
STRATEGIES FOR CONTINUED GROWTH Continued Geographic Expansion of Expansion Services Leveraging people, process technology, and deep Leveraging Data penetration into BioPharma Champions Growth Engine
Slide 26: Company Contacts
Ronnie Morris, MD - President and CEO (201) 808-8401 RMorris@ChampionsOncology.com David Miller, MBA - CFO (551) 206-8104 DMiller@ChampionsOncology.com COMPANY CONTACTS NASDAQ: CSBR 16
Champions Oncology — Investor Presentation (January 2020) on 6ix